Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Daiichi Sankyo S/Adr (OP:DSNKY)

19.06 -0.31 (-1.60%)
Streaming Delayed Price Updated: 9:41 AM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Daiichi Sankyo S/Adr

< Previous 1 2 3 Next >
News headline image
AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting ↗
 
Via Benzinga
News headline image
Is Gilead Sciences a Good Stock to Buy Now? ↗
Gilead Sciences' breast cancer drug, Trodelvy, just took a big step forward. 
Via The Motley Fool
News headline image
AstraZeneca’s Next “Wonder Drug” ↗
Enhertu is an antibody-drug conjugate, a type of therapy designed to do minimal damage to healthy, non-cancerous cells. Wall Street analysts believe that Enhertu has the potential to become a key... 
Via Talk Markets
News headline image
Daiichi Sankyo Seeks Approval In Japan For Its mRNA-Based COVID-19 Vaccine ↗
 
Via Benzinga
News headline image
AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs ↗
 
Via Benzinga
News headline image
AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients ↗
 
Via Benzinga
News headline image
This Cancer Focused Stock Has 60% Potential Upside, Bullish Analyst Says ↗
 
Via Benzinga
News headline image
European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs ↗
 
Via Benzinga
News headline image
With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma ↗
 
Via Benzinga
News headline image
3 Top Stocks to Invest In Right Now ↗
Every investor is looking for the top stocks to invest in. These three options will provide you with both offense and defense. 
Via InvestorPlace
News headline image
Seagen Suffers Loss In Arbitration Dispute Over ADC Technology ↗
 
Via Benzinga
News headline image
AstraZeneca-Daiichi's Flagship Breast Cancer Drug Improves Survival In Late-Stage Study ↗
 
Via Benzinga
News headline image
Daiichi-AstraZeneca's Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation ↗
 
Via Benzinga
News headline image
AstraZeneca's Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients ↗
 
Via Benzinga
News headline image
Daily Biotech Pulse: KKR Invests In Medicine Start-Up, Revelation Bio Aces Allergic Rhinitis Study, Tonix Pharma Ends COVID-19 Antiviral Pact ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
AstraZeneca's Enhertu Wins European Approval For Pretreated Breast Cancer Setting ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
EMA's Advisory Committee Backs Approval For AstraZeneca's Targeted Breast Cancer Therapies ↗
 
Via Benzinga
News headline image
AstraZeneca-Daiichi Breast Cancer Drug Cuts Disease Progression Or Death Risk By Almost 50% ↗
 
Via Benzinga
News headline image
Daiichi Sankyo - AstraZeneca's Enhertu Receives Third Breakthrough Therapy Tag In Breast Cancer ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: Regeneron Acquires Checkmate Pharma, Moderna's Bivalent Booster COVID-19 Vaccine Update, Priority Review For AstraZeneca's Enhertu ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Daiichi Sankyo - AstraZeneca's Enhertu Receives Priority Review In US For Lung Cancer ↗
 
Via Benzinga
News headline image
Seagen Wins $42M Patent Claim Against Daiichi In Cancer Drug Case ↗
A jury in Marshall, Texas, awarded Seagen Inc (NASDAQ: SGEN)  
Via Benzinga
News headline image
AstraZeneca's Enhertu Meets Primary Endpoint In HER2-Low Breast Cancer Setting ↗
AstraZeneca plc (NASDAQ: AZN) said that Enhertu prolonged survival and slowed the progression of metastatic breast cancer with low levels of a protein known as HER2... 
Via Benzinga
News headline image
Here's My Top Value Stock To Buy Right Now ↗
EXEL is working on further expanding cabozantinib’s label. It is currently evaluating the drug as a single agent and in combination with immune checkpoint inhibitors across various indications. 
Via Talk Markets
News headline image
Esperion Chops 40% Workforce As Launch Of Cholesterol Medication Falters ↗
Esperion Therapeutics Inc's (NASDAQ: ESPR) cholesterol drug marketing strategy has soured badly, as it has been struggling to sell its heart disease pill for more than a... 
Via Benzinga
News headline image
Here's Why Everyone's Talking About AstraZeneca Right Now ↗
The company's next-generation treatment for breast cancer could become the new standard of care. 
Via The Motley Fool
News headline image
AstraZeneca's Enhertu Posts Substantial Clinical Benefit Over Roche's Kadcyla In Breast Cancer Trials ↗
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo's (OTC: DSNKY) Enhertu have shown some striking data in late-stage breast cancer trials and early solid tumor... 
Via Benzinga
News headline image
AstraZeneca-Daiichi Sankyo Share Detailed Enhertu Data In Gastric Cancer ↗
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSNKY) announced detailed results from the positive DESTINY-Gastric02 Phase 2 trial of Enhertu... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.